New therapeutics for soft-tissue sarcomas in adults.
von Mehren
Margaret
M
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004149:Dioxoles / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D011494:Protein Kinases; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012509:Sarcoma / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D000077606:Trabectedin; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004149:Dioxoles; D004791:Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C515074:ridaforolimus; D013792:Thalidomide; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; D000077606:Trabectedin; D020123:Sirolimus